Clinical trials: Protein
Preeclampsia
Comparison of Random Spot Urine Protein:Creatinine Ratio to 24-Hour Timed Urine Protein Collection in the Evaluation of Preeclampsia
This is a non-inferiority, prospective study of the relationship between the 24-hour urine protein collection and spot protein:creatinine ratio in the diagnosis of preeclampsia involving a sample of 18-45 year-old pregnant women…
- Trial name
- P:C Ratio (NCT01447290)
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Mike O'Callaghan Military Hospital
Severe Periodontitis, Acute Inflammatory Response
IFI16 is a Periodontitis Modulating Protein
To characterize the expression of Interferon gamma inducible protein 16 (IFI16) and Absent in melanoma 2 (AIM2) in gingival tissues in an inflammatory response using an acrylic mouthguard (also referred to as a stent) induced…
- Trial name
- IFI (NCT03513497)
- Testing
- Customized acrylic mouthguard
- Where
- United States
- Volunteers
- 69 people, healthy volunteers welcome
- Sponsor
- University of North Carolina, Chapel Hill
Type-2 Diabetes, Overweight
Nutritional Intervention With Moderately High-protein, Low-glycemic Load Products in Type-2 Diabetes Patients
The main objective of this study is to evaluate the effects on anthropometric, glucose metabolism and lipid profile biomarkers of exchanging with high-protein, low-glycemic index products (40-30-30) the habitual breakfast…
- Trial name
- NCT01264523
- Testing
- Chronologically scheduled snacking with 40-30-30 products
- Where
- Spain
- Volunteers
- 17 people
- Sponsor
- Clinica Universidad de Navarra, Universidad de Navarra
Cancer of Unknown Primary
Phase II Trial of Lu-177 FAP-2286 in Patients With Carcinoma of Unknown Primary
The aim of the study is to test if a new radionuclide therapy, called 177-Lu-FAP-2286, works to treat cancer in patients with Cancer of Unknown Primary (CUP).
- Trial name
- Lu-FAP CUP (NCT07434180)
- Testing
- 177Lu-FAP-2286
- Where
- Australia
- Volunteers
- 20 people
- Sponsor
- Peter MacCallum Cancer Centre, Australia
Breast Cancer
Feasibility of Ultrasound Microbubble Contrast-Enhanced (CEUS) Sentinel Lymph Node Imaging With Guided Biopsy in Breast Cancer Patients
The goal of this clinical research is to learn if an ultrasound contrast agent called OPTISON (perflutren protein type A) is effective in finding sentinel lymph nodes before surgery.
- Trial name
- NCT02321527
- Testing
- Perflutren Protein-Type A Microspheres Injectable Suspension, Contrast-Enhanced Ultrasound (CEUS), Biopsy + Radioactive Seed Placement
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- M.D. Anderson Cancer Center
Lymphoma, Multiple Myeloma
Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Relapsed or Refractory Multiple Myeloma
The purpose of the study is to determine whether the addition of Elotuzumab to Lenalidomide/low-dose Dexamethasone will increase the progression free survival (PFS).
- Trial name
- ELOQUENT - 2 (NCT01239797)
- Testing
- Lenalidomide, Dexamethasone, Dexamethasone (Oral)
- Where
- 216 sites in United States, Australia and 21 more
- Volunteers
- 646 people
- Sponsor
- Bristol-Myers Squibb
Multiple Myeloma, Plasma Cell Dyscrasia
Plerixafor Harvesting And No Chemotherapy for Transplantation of Autologous STem Cells In Cancer (PHANTASTIC)
To assess the efficacy and toxicity of plerixafor (AMD 3100) together with granulocyte-colony stimulating factor (G-CSF) for stem cell mobilisation, in patients with myeloma or lymphoma requiring high dose chemotherapy with stem…
- Conditions
- Multiple Myeloma, Plasma Cell Dyscrasia, Lymphoma, Lymphoproliferative Disorders
- Trial name
- PHANTASTIC (NCT01186224)
- Testing
- Plerixafor and G-CSF
- Where
- United Kingdom
- Volunteers
- 60 people
- Sponsor
- University of Liverpool
Relapsed or Refractory Multiple Myeloma
A Modular, Phase I/II, Multicentre Study to Evaluate AZD4045, in Participants With Relapsed or Refractory Multiple Myeloma
The purpose of this study is to assess the safety, tolerability, preliminary efficacy, cellular kinetics, and other exploratory endpoints of AZD4045 as a monotherapy and in association with daratumumab and aldesleukin for the…
- Trial name
- NCT07681596
- Testing
- AZD4045, Daratumumab, Aldesleukin
- Where
- 12 sites in United States, Australia
- Volunteers
- 101 people
- Sponsor
- AstraZeneca
Hemophilia B
Gene Therapy for Hemophilia B Patients Aged 12-18 Years Old
This is a Phase 1, open- label, non- randomized, uncontrolled, single dose pilot study to evaluate the safety, tolerability and efficacy of a single intravenous infusion of BBM-H901 in hemophilia B subjects with ≤2IU/dl residual…
- Trial name
- NCT05709288
- Testing
- BBM-H901
- Where
- China
- Volunteers
- 9 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Inflammatory Bowel Disease, Crohn's Disease
Low-dose CT Using Iterative Reconstruction in Patients With Inflammatory Bowel Disease
The purpose of this study is to validate the use of a low-dose computed tomography (CT) protocol and facilitate reduced radiation doses in patients with inflammatory bowel disease (IBD).
- Conditions
- Inflammatory Bowel Disease, Crohn's Disease, Ulcerative Colitis
- Trial name
- NCT01244386
- Where
- Ireland
- Volunteers
- 250 people
- Sponsor
- University College Cork
Malignant Pleural Effusion
A Phase I Study Evaluating SCB-313(Recombinant Human TRAIL-Trimer Fusion Protein) for the Treatment of Malignant Pleural Effusion
To evaluate the safety and tolerability of single dose of SCB-313 by intrapleural injection.To evaluate the safety and tolerability of repeated dose of SCB-313 by intrapleural injection once a day for 3 days, and to determine the…
- Trial name
- NCT04123886
- Testing
- SCB-313
- Where
- China
- Volunteers
- 14 people
- Sponsor
- Sichuan Clover Biopharmaceuticals, Inc.
Healthy Participants
A Research Study Looking at New Protein-based Tablets in Healthy Men - Oral Formulation III
In this study, a known medicine called 'semaglutide' will be tested in two different tablet versions. The two tablets differ in the way these have been manufactured.
- Trial name
- NCT06097390
- Testing
- Semaglutide
- Where
- Canada
- Volunteers
- 121 people, healthy volunteers welcome
- Sponsor
- Novo Nordisk A/S
Multiple Myeloma Stage I
Daratumumab Intensified Treatment to Eligible MM New Patients CTD-Dara Induction, Follow by Dara Consolidation
The best induction protocol to eligible multiple myeloma patients was not established. Combination of three drugs demonstrated better outcomes than two drugs combo.
- Trial name
- MAXDARA (NCT03792620)
- Testing
- Cyclo Thal Dex Daratumumab
- Where
- Brazil
- Volunteers
- 20 people
- Sponsor
- Grupo de Estudos Multicentricos em Onco-Hematologia
Smoldering Multiple Myeloma
Smoldering Myeloma High-Risk Patient Observation and Longitudinal Insight Trial
The purpose of this study is to define the natural history of high-risk smoldering myeloma in a modern cohort of patients undergoing close standard of care follow-up with diffusion weighted whole body magnetic resonance imaging.
- Trial name
- SPOTLIGHT (NCT06212323)
- Testing
- Patients with smoldering myeloma undergoing active surveillance with diffusion weighted whole body MRI.
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- University of Utah
Multiple Myeloma
Long-term Follow-up Study in Subjects With Multiple Myeloma Previously Treated With GC012F Injection
This is an open-label, multicenter, observational study (non-interventional study) to evaluate the long-term safety, efficacy, and in vivo pharmacokinetic persistence of CAR-T cells in subjects treated with GC012F Injection
- Trial name
- NCT07833046
- Testing
- No Intervention: Observational Cohort
- Where
- China
- Volunteers
- 40 people
- Sponsor
- RenJi Hospital
Multiple Myeloma, Blood Stem Cell Transplant Failure
Assessment of Mobilization Cost for Multiple Myeloma Using 2 Different Mobilization Strategies
This is a retrospective observational cohort database analysis. The study will review retrospectively the records of patients undergoing a first peripheral blood stem cell mobilization for multiple myeloma in the databases from…
- Trial name
- MOZOBIL (NCT02997813)
- Where
- 9 sites in France
- Volunteers
- 112 people
- Sponsor
- Intergroupe Francophone du Myelome
Giant Cell Arteritis, Polymyalgia Rheumatica
Assessing Biomarker in Giant Cell Arteritis and Polymyalgia Rheumatic
The GCAIO study is an innovative, multimodal research initiative designed to enhance the understanding, diagnosis, and management of giant cell arteritis (GCA) and frequently associated polymyalgia rheumatica (PMR).
- Trial name
- GCAIO (NCT06460142)
- Testing
- Aortic/ cardiac magnetic resonance imaging, Vascular ultrasound, Transorbital Ultrasound
- Where
- Germany
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- University of Bonn
Multiple Myeloma
Study to Determine the Maximum Tolerated Dose for the Combination of Pomalidomide, Bortezomib and Low-Dose Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma
The purpose of this study is to determine the maximum tolerated dose (MTD) of pomalidomide in combination with bortezomib and low-dose dexamethasone in subjects with relapsed or refractory multiple myeloma
- Trial name
- NCT01497093
- Testing
- Pomalidomide, Bortezomib, Dexamethasone
- Where
- 6 sites in United States
- Volunteers
- 34 people
- Sponsor
- Celgene
Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma
CS1-CAR T Therapy Following Chemotherapy in Treating Patients With Relapsed or Refractory CS1 Positive Multiple Myeloma
This phase I trial studies the side effects and best dose of CS1-chimeric antigen receptor (CAR) T therapy after chemotherapy in treating patients who have CS1 positive multiple myeloma that has come back (relapsed) or does not…
- Trial name
- NCT03710421
- Testing
- CS1-CAR T Therapy, Cyclophosphamide, Fludarabine
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- City of Hope Medical Center
Chronic Kidney Diseases
Ghrelin and Obestatin in CKD Children
Protein energy wasting (PEW) is a complex syndrome associated with different underlying illnesses and characterized by loss of muscle, with or without loss of fat.
- Trial name
- NCT03171116
- Testing
- none intervention
- Volunteers
- 154 people
- Sponsor
- Azienda Ospedaliero Universitaria Maggiore della Carita